[go: up one dir, main page]

CN108251380A - A kind of 7E8 cell strain of monoclonal antibody preparation method of resistant to foot and mouth disease 3B albumen and application - Google Patents

A kind of 7E8 cell strain of monoclonal antibody preparation method of resistant to foot and mouth disease 3B albumen and application Download PDF

Info

Publication number
CN108251380A
CN108251380A CN201810160140.3A CN201810160140A CN108251380A CN 108251380 A CN108251380 A CN 108251380A CN 201810160140 A CN201810160140 A CN 201810160140A CN 108251380 A CN108251380 A CN 108251380A
Authority
CN
China
Prior art keywords
albumen
mouth disease
foot
monoclonal antibody
resistant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810160140.3A
Other languages
Chinese (zh)
Inventor
魏婕
魏玉荣
苗书魁
马文戈
黄炯
汪萍
郭会玲
米晓云
薛英
王延
薛晶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Veterinary Research Institute Xinjiang Academy Of Animal Sciences
Original Assignee
Veterinary Research Institute Xinjiang Academy Of Animal Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veterinary Research Institute Xinjiang Academy Of Animal Sciences filed Critical Veterinary Research Institute Xinjiang Academy Of Animal Sciences
Priority to CN201810160140.3A priority Critical patent/CN108251380A/en
Publication of CN108251380A publication Critical patent/CN108251380A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1009Picornaviridae, e.g. hepatitis A virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/085Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • G01N2333/09Foot-and-mouth disease virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/20Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

7E8 cell strain of monoclonal antibody preparation method and application the invention discloses a kind of resistant to foot and mouth disease 3B albumen, the bacterial strain on October 25th, 2017, are preserved in China typical culture collection center, deposit number is CCTCC NO:C2017228.The present invention can be with the content of 3B albumen in qualitative detection serum, whether so as to infer mouth disease virus infection.Mainly for detection of foot and mouth disease virus non-structural protein 3B antigens in animal blood serum, monitor and assess suitable for animal population infection state, find early stage subclinical infection and quarantine of passing in and out, do not limited by serotype.

Description

A kind of 7E8 cell strain of monoclonal antibody preparation method of resistant to foot and mouth disease 3B albumen and Using
Technical field
The invention belongs to biotechnology, specifically, being related to a kind of 7E8 monoclonal antibodies of resistant to foot and mouth disease 3B albumen Cell strain preparation method and application.
Background technology
FMD is the artiodactyls deadly infectious disease as caused by FMDV, and World Organization for Animal Health (OIE) is included in must The animal epidemic that must be notified to.Disease propagation is fast, host range is wide, incidence is high, and great threat is formed to animal husbandry development.In recent years Carry out China's livestock breeding industry to quickly grow, aftosa is great potential threat.Policy is slaughtered with what developed country was usually taken Difference, developing country generally control the disease using immune method.Therefore, how immune animal is quickly and reliably distinguished And infection animal, it is particularly important for the anti-system of FMD and international trade.After zoogenetic infection FMDV, structure can be generated Protein antibodies, and NSP antibody can be generated, and vaccine immunity animal mainly induces body to generate FMDV structural proteins antibody, with knot Structure albumen is compared, and the variation of non-structural protein is less, relatively conservative.In FMD diagnosis, distinguish immune animal and natural infection is moved Object is a highly important content, differentiates that natural infected animal and immune animal are also that OIE judges a country whether there is FMD Popular foundation.In recent years, the diagnostic method of detection FMDVNSP antibody is established successively, to distinguish FMDV infection animals and note Penetrate vaccine animal.
The NSP of FMDV refers to all by virus other than capsid protein 1A, 1B, 1C, 1D and their precursor protein The albumen of viral capsid composition is encoded but is not involved in, before maturation protein L, 2A, 2B, 2C, 3A, 3B, 3C, 3D and they Body.The 3B albumen of FMDV is by the connected but not exactly the same gene code in non-structural protein P3 code areas 3, size difference For 69bp, 72bp, 72bp and 3 kinds of different 3B albumen (VPg1~3) are generated, this phenomenon is rare in RNA virus.VPg albumen Participate in the starting synthesis of RNA virus and the formation of capsid.Since V Pg carry pUpU structures and newly synthesized filial generation RNA phases Even, so VPg is considered as the primer of picornavirus R NA synthesis.This special rna replicon mode is transcribed with host mRNA It is different.Thus, when host RN A synthesis is suppressed, have no effect on the synthesis of FMDVRNA.The copy number and RNA of VPg genes Virus appeal be proportionate, VPg mutation viral lifecycle will be caused to extend, this also means that the synthesis of polymeric protein and Processing is postponed, and infectious number of particles is reduced.At present, the research about FDMV3B albumen is less, it is in virus replication In effect and disclosed completely not yet with the interaction of host.
Invention content
The purpose of the present invention is to provide a kind of 7E8 cell strain of monoclonal antibody preparation methods of resistant to foot and mouth disease 3B albumen And application, to express albumen 3B as mice immunized with antigen, by hybridoma technology obtain specific hybridoma cell strain and Its monoclonal antibody, establishes the method for competitive ELISA detection method detection 3B albumen, and assembles kit, to foot and mouth disease virus Infection animal carries out antidiastole.
Its specific technical solution is:
A kind of 7E8 cell strain of monoclonal antibody of resistant to foot and mouth disease 3B albumen, the bacterial strain on October 25th, 2017, are protected China typical culture collection center is hidden in, deposit number is CCTCC NO:C2017228.Depositary institution address:Hubei Province is military Han Shi Wuchang Districts Luo Jia Shan (Bayi Road 299).
Further, the nucleotide sequence of the bacterial strain such as SEQ:ID:NO:Shown in 1.
GAAGGACCCTACACCGGTCCACTCGAGCGTCAAAAACCTCTGAAAGTGAGAGCCAAGCTCCCACAGCAGGAGGGG CCCTACGCTGGTCCGATGGAGAGACAGAAACCGCTGAAAGTGAAAGTGAAAGCCCCGGTCGTTAAGGAAGGACCTTA CG AAGGACCGGTGAAGAAACCTGTCGCTTTGAAAGTGAAAGCAAAGAACTTGATTGTCACTGAG
A kind of preparation method of the 7E8 cell strain of monoclonal antibody of resistant to foot and mouth disease 3B albumen, includes the following steps:
Step 1,3B protein immunization mouse;
Step 2 takes spleen and SP2/0 cells to carry out cell fusion;
Step 3, the cell strain of ELISA screening specificity and by positive hole cell monoclonal;
It is prepared by step 4, ascites;
Step 5, Protein G affinity purifications are monoclonal antibody-purified.
The 7E8 cell strain of monoclonal antibody of resistant to foot and mouth disease 3B albumen of the present invention is preparing detection aftosa 3B albumen examinations The application of agent box process.
Compared with prior art, beneficial effects of the present invention are:
The present invention can be with the content of 3B albumen in qualitative detection serum, whether so as to infer mouth disease virus infection.Mainly For detecting foot and mouth disease virus non-structural protein 3B antigens in animal blood serum, monitor and comment suitable for animal population infection state Estimate, find early stage subclinical infection and quarantine of passing in and out, do not limited by serotype.
Description of the drawings
Fig. 1 is 3B expression proteantigen SDS-PAGE electrophoresis;
Fig. 2 is monoclonal antibody SDS-PAGE electrophoresis.
Specific embodiment
Technical scheme of the present invention is described in more detail with reference to specific embodiment.
A kind of preparation method of the 7E8 cell strain of monoclonal antibody of resistant to foot and mouth disease 3B albumen, which is characterized in that including following Step:
Step 1: immune programme
Table 1
Step 2 exempts from rear mice serum bioactivity
Table 2
Note:
Coating condition:10 μ g/ml envelope antigens, 100 μ l/well, 37 DEG C of 150 μ l/ of water-bath coating 2.5h → confining liquid Well37 DEG C of water-bath 2h;
ELISA reaction conditions:100 μ l/well of primary antibody, 37 DEG C of 100 μ l/well of water-bath 1.5h → sheep anti-mouse igg-HRP 37 DEG C of 100 μ l/well color development at room temperature 15min → 1N hydrochloric acid of water-bath 1.5h → TMB, 50 μ l/well terminations → microplate reader OD450 is read Value.
Step 3, fusion mice serum bioactivity
Table 3
Note:
Coating condition:10 μ g/ml envelope antigens, 100 μ l/well, 37 DEG C of 150 μ l/ of water-bath coating 2.5h → confining liquid Well37 DEG C of water-bath 2h;
Reaction condition:50 μ l/well of primary antibody, 37 DEG C of water-bath 45min → sheep anti-mouse igg-HRP 50 μ l/well, 37 DEG C of water Bathe 50 μ l/well color development at room temperature 10min → 1N hydrochloric acid of 45min → TMB, 50 μ l/well terminations → microplate reader OD450 readings.
Step 4, cell fusion
By the mouse boosting cell being immunized and SP2/0 myeloma cell with 5~7:1 ratio is merged with 5% PEG6000 Mouse boosting cell from the mouse spleen being immunized is taken out and is added dropwise in SP2/0 myeloma cell, side edged mixes rhythm, Later, it is stored at room temperature 10 minutes.And by the cell seeding after fusion in containing thymus gland sertoli cell, HAT, 20% calf serum, In the semisolid culturemedium of Methyl-Cellulose methylcellulose and ISCOVE culture solutions.In 37 DEG C, 5%CO2Incubator is trained After supporting 7-10 days, it is seen that there are a large amount of hybridoma clones to occur in semisolid culturemedium.It is provoked gram with sterile water dropper under the microscope It is grand and plant in being covered with thymus gland sertoli cell as feeder cells, the 96 hole cells of HAT, 20% calf serum and ISCOVE culture solutions In culture plate, with infinite dilution method, a clone i.e. detectable supernatant antibody titer after a week is only cultivated per hole.
The screening of step 5, anti-3B antibody-secretings positive colony
The clone of the anti-3B antibody-secretings positive is screened using ELISA method.
Step 6, ascites prepare with it is monoclonal antibody-purified.
There was only heavy chain and light chain after monoclonal antibody SDS-PAGE after purification as can be seen from Figure 2.
The foregoing is only a preferred embodiment of the present invention, protection scope of the present invention is without being limited thereto, it is any ripe Those skilled in the art are known in the technical scope of present disclosure, the simple of technical solution can be become apparent to Variation or equivalence replacement are each fallen in protection scope of the present invention.
Sequence table
<110>Xinjiang herding academy of sciences veterinary institute
<120>A kind of 7E8 cell strain of monoclonal antibody preparation method of resistant to foot and mouth disease 3B albumen and application
<160> 1
<170> SIPOSequenceListing 1.0
<210> 2
<211> 216
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 2
gaaggaccct acaccggtcc actcgagcgt caaaaacctc tgaaagtgag agccaagctc 60
ccacagcagg aggggcccta cgctggtccg atggagagac agaaaccgct gaaagtgaaa 120
gtgaaagccc cggtcgttaa ggaaggacct tacgaaggac cggtgaagaa acctgtcgct 180
ttgaaagtga aagcaaagaa cttgattgtc actgag 216

Claims (4)

1. a kind of 7E8 cell strain of monoclonal antibody of resistant to foot and mouth disease 3B albumen, which is characterized in that the bacterial strain is in 2017 10 The moon 25, China typical culture collection center is preserved in, deposit number is CCTCC NO:C2017228.
2. the 7E8 cell strain of monoclonal antibody of resistant to foot and mouth disease 3B albumen according to claim 1, which is characterized in that described The nucleotide sequence of bacterial strain such as SEQ:ID:NO:Shown in 1.
3. a kind of preparation method of the 7E8 cell strain of monoclonal antibody of resistant to foot and mouth disease 3B albumen, which is characterized in that including following step Suddenly:Step 1,3B protein immunization mouse;
Step 2 takes spleen and SP2/0 cells to carry out cell fusion;
Step 3, the cell strain of ELISA screening specificity and by positive hole cell monoclonal;
It is prepared by step 4, ascites;
Step 5, Protein G affinity purifications are monoclonal antibody-purified.
4. the 7E8 cell strain of monoclonal antibody of resistant to foot and mouth disease 3B albumen described in claim 1 is preparing detection aftosa 3B albumen The application of kit process.
CN201810160140.3A 2018-02-26 2018-02-26 A kind of 7E8 cell strain of monoclonal antibody preparation method of resistant to foot and mouth disease 3B albumen and application Pending CN108251380A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810160140.3A CN108251380A (en) 2018-02-26 2018-02-26 A kind of 7E8 cell strain of monoclonal antibody preparation method of resistant to foot and mouth disease 3B albumen and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810160140.3A CN108251380A (en) 2018-02-26 2018-02-26 A kind of 7E8 cell strain of monoclonal antibody preparation method of resistant to foot and mouth disease 3B albumen and application

Publications (1)

Publication Number Publication Date
CN108251380A true CN108251380A (en) 2018-07-06

Family

ID=62745376

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810160140.3A Pending CN108251380A (en) 2018-02-26 2018-02-26 A kind of 7E8 cell strain of monoclonal antibody preparation method of resistant to foot and mouth disease 3B albumen and application

Country Status (1)

Country Link
CN (1) CN108251380A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120315295A1 (en) * 2010-07-01 2012-12-13 Rieder Aida E Development of a Marker Foot and Mouth Disease Virus Vaccine Candidate That is Attenuated in the Natural Host
CN107201346A (en) * 2017-03-22 2017-09-26 中国农业科学院兰州兽医研究所 The strain of aftosa marker vaccine and its construction method and application of 3B albumen Dominant Epitopes missing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120315295A1 (en) * 2010-07-01 2012-12-13 Rieder Aida E Development of a Marker Foot and Mouth Disease Virus Vaccine Candidate That is Attenuated in the Natural Host
CN107201346A (en) * 2017-03-22 2017-09-26 中国农业科学院兰州兽医研究所 The strain of aftosa marker vaccine and its construction method and application of 3B albumen Dominant Epitopes missing

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MASON.P.W等: "Foot-and-mouth disease virus O, strain Tibet/CHA/99, complete genome", 《GENBANK》 *
MING YANG等: "Development of a Competitive Enzyme-Linked Immunosorbent Assay for Detection of Antibodies against the 3B Protein of Foot-and-Mouth Disease Virus", 《CLINICAL AND VACCINE IMMUNOLOGY》 *
李永亮: "口蹄疫病毒3B非结构蛋白单克隆抗体的制备及应用", 《中国优秀硕士学位论文全文数据库农业科技辑》 *
杨沁: "C型口蹄疫病毒单克隆抗体的制备与鉴定", 《甘肃农业大学学报》 *

Similar Documents

Publication Publication Date Title
CN103266091B (en) A type foot-and-mouth disease recombinant vaccine strains and preparation method and application thereof
JPH06506583A (en) Plant viruses modified as vectors
CN110759973B (en) Cell strain for expressing African swine fever virus CD2v protein and application thereof
CN112175086B (en) Monoclonal antibody of anti-porcine epidemic diarrhea virus nsp13 protein and application
CN105820257B (en) Adenovirus hominis epitope chimeric protein and its preparation, application
CN107201346B (en) Foot-and-mouth disease marker vaccine strain lacking dominant epitope of 3B protein and its construction method and application
CN114854698B (en) O-type foot-and-mouth disease virus strain with improved replication titer, construction method and application thereof
CN113061587A (en) An antigenic spectrum expanded O-type foot-and-mouth disease virus strain and its construction method and application
CN106520710A (en) Preparation method and application of live vector vaccine for expressing duck Tembusu virus (DTMUV) prm and E protein recombinant Newcastle disease virus (NDV)
CN103301476A (en) Porcine epizootic diarrhea gene recombinant vaccine as well as constructed primer and construction method thereof
CN105400745B (en) A kind of porcine reproductive and respiratory syndrome virus gene engineered strain and its inactivated vaccine and vaccine preparation method
Vitti et al. Cucumber mosaic virus as the expression system for a potential vaccine against Alzheimer's disease
CN108251380A (en) A kind of 7E8 cell strain of monoclonal antibody preparation method of resistant to foot and mouth disease 3B albumen and application
CN101451151A (en) Method for producing biological active outcome by using tumour cell
CN109306007B (en) Anti-porcine reproductive and respiratory syndrome virus nsp4 protein genetically engineered antibody and its application
CN115896043B (en) A kind of O-type foot-and-mouth disease vaccine candidate strain and its construction method and application
CN100543139C (en) HCV Compound Multi-epitope Transgenic Plant Oral Vaccine
CN117305311A (en) Application of heterologous expression of tardigrade Dsup gene in rice to improve radiation tolerance of rice
CN105274116A (en) Nucleic acid for preparation of humanized antibody and application of nucleic acid
CN113425838B (en) Recombinant PRRSV virus-like particle antigen-antibody complex and preparation method thereof
CN110846285A (en) Pseudorabies virus gene deletion strain, porcine pseudorabies inactivated vaccine, and preparation method and application thereof
CN103898066B (en) A kind of influenza A virus Vero cell acclimatization to cold strain and application thereof
CN111471657A (en) Construction method of PRV gE/gI double-gene deletion strain for expressing ASFV P30 protein
CN109517044A (en) A kind of Porcine epidemic diarrhea virus gene engineering antigen and antibody
CN105002195B (en) A kind of pig blue-ear disease recombinant vaccine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180706